Medical devices, healthcare technology and the business of care
510(k) clearance · K251680

Biosteon Screw

Biocomposites, Ltd. · Decision date Feb 17, 2026

FDA DECISIONK251680

What did the FDA decide?

FDA records K251680 as a 510(k) premarket notification, with a decision dated Feb 17, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Orthopedic
Decision date
Feb 17, 2026

FDA source record

Regulatory record facts

Identifier
K251680
Regulatory pathway
510(k) premarket notification
Product code
MAI
Decision code
SESE
Decision date
Feb 17, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Fastener, Fixation, Biodegradable, Soft Tissue.

Product code
MAI
FDA device class
2

FDA decision timeline

  1. K251680 received

    Application receipt date recorded by FDA.

  2. K251680 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code MAI

Product / regulatory recordCompanyPathwayDecision dateSource
Surgical Fusion Technologies GmbH510(k) clearanceNov 5, 2026FDA
ARTHREX, INC.510(k) clearanceAug 7, 2026FDA
ARTHREX, INC.510(k) clearanceMay 28, 2026FDA
Surgical Fusion Technologies GmbH510(k) clearanceMar 27, 2026FDA
OSSIO , Ltd.510(k) clearanceFeb 24, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biocomposites, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Keele

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records